在儿童喘恶化中对德克萨米他剂量策略的评估
Irene R Kelly1, Thomas Laudone1, Richard Lichenstein2
1School of Pharmacy, University of Maryland, Baltimore, MD (IRK, TL, KAP).
概括
针对儿科喘恶化症的标准化剂量甲并没有增加复诊次数,但缩短了住院时间. 这种方法可以提高坚持,并提供有利的结果.
科学领域:
- 儿科急救医学 儿科急救医学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘恶化是儿童急诊室访问的常见原因之一.
- 德克萨米他是用于治疗儿童喘恶化症的关键皮质类固醇.
- 目前德克萨米他的剂量策略各不相同,有些是基于体重的,有些是标准化的.
研究的目的:
- 为了比较儿童喘恶化的医疗保健利用率,使用标准剂量治疗德克萨米他与基于体重的剂量治疗.
- 评估不同德克萨米他剂量策略对患者治疗结果和资源使用的影响.
主要方法:
- 对患有喘恶化症的儿科患者 (2-17岁) 的回顾性单中心研究.
- 纳入标准:接受了德克萨米他,被诊断患有喘 (ICD-10代码).
- 主要结局:30日和90天的重复访问急诊室;次要结局:住院,输管,停留时间,不良事件.
主要成果:
- 在标准化和基于体重的德甲组之间,在30或90天的再访中没有显著差异.
- 标准化剂量组的停留时间较短,并减少了ipratropium和的使用.
- 在基于体重的组中,住院率较低;不良事件 (吐,高血糖,高血压) 在各组中相似.
结论:
- 在儿科喘恶化中,标准化德克萨米他剂量与有利的结果有关,包括更短的住院时间.
- 这一策略可能会简化治疗,并可能改善坚持治疗.
- 可能需要进一步的研究,以充分阐明住院率差异.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
266
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
266
01:23Inhaled Medications
279
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
279
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
01:17Drugs Used in Lower Respiratory Disorders: Overview
450
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
450
01:26COPD: Management Using Bronchodilators and Corticosteroids
213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213